دورية أكاديمية
Efficacy and safety evaluation of Azvudine in the prospective treatment of COVID-19 based on four phase III clinical trials.
| العنوان: | Efficacy and safety evaluation of Azvudine in the prospective treatment of COVID-19 based on four phase III clinical trials. |
|---|---|
| المؤلفون: | Zhu KW; Office of Pharmacovigilance, Guangzhou Baiyunshan Pharmaceutical Holding Co., Ltd., Baiyunshan Pharmaceutical General Factory, Guangzhou, Guangdong, China. |
| المصدر: | Frontiers in pharmacology [Front Pharmacol] 2023 Aug 24; Vol. 14, pp. 1228548. Date of Electronic Publication: 2023 Aug 24 (Print Publication: 2023). |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Media] Country of Publication: Switzerland NLM ID: 101548923 Publication Model: eCollection Cited Medium: Print ISSN: 1663-9812 (Print) Linking ISSN: 16639812 NLM ISO Abbreviation: Front Pharmacol Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: [Lausanne : Frontiers Media] |
| مستخلص: | Azvudine (FNC) is a synthetic nucleoside analog used to treat adult patients living with human immunodeficiency virus-1 (HIV-1) infection with high viral load. After phosphorylation, Azvudine inhibits RNA-dependent RNA polymerase, leading to the discontinuation of RNA chain synthesis in viruses. In addition, Azvudine is the first dual-target nucleoside oral drug worldwide to simultaneously target reverse transcriptase and viral infectivity factors in the treatment of HIV infection. On 9 August 2022, Azvudine was incorporated into the Guidelines for the Diagnosis and Treatment of Coronavirus Disease 2019 (version ninth) issued by the National Health Commission and the National Administration of Traditional Chinese Medicine. The recommended oral dose of Azvudine for the treatment of moderate coronavirus disease 2019 (COVID-19) is 5 mg once daily, and the duration of Azvudine treatment should not exceed 14 days. Four phase III clinical trials were performed during 2020-2022 to evaluate the efficacy and safety of Azvudine in the treatment of COVID-19. The results revealed that Azvudine could reduce nucleic acid-negative conversion time, viral load, and time to improvement in clinical conditions in patients with moderate COVID-19. In addition, Azvudine exhibited good safety and tolerance. Thereafter, Azvudine was incorporated into the Chinese guidelines and expert consensus for the treatment of COVID-19 and was highly approbated. Furthermore, Azvudine was also included in the Chinese guidelines for HIV infection. Competing Interests: Author K-WZ was employed by Guangzhou Baiyunshan Pharmaceutical Holding Co., Ltd. Baiyunshan Pharmaceutical General Factory. (Copyright © 2023 Zhu.) |
| References: | Viruses. 2022 May 04;14(5):. (PMID: 35632703) Expert Opin Ther Pat. 2021 Apr;31(4):325-337. (PMID: 33475441) Nat Rev Microbiol. 2021 Nov;19(11):685-700. (PMID: 34535791) ACS Omega. 2022 Jun 13;7(25):21385-21396. (PMID: 35785294) Hum Vaccin Immunother. 2023 Aug 1;19(2):2229704. (PMID: 37433429) Signal Transduct Target Ther. 2020 Oct 10;5(1):236. (PMID: 33040075) Chem Biol Interact. 2021 Jul 1;343:109480. (PMID: 33887223) Med Chem Res. 2023;32(2):326-341. (PMID: 36593869) Eur Respir Rev. 2021 Oct 20;30(162):. (PMID: 34670808) Nat Rev Mol Cell Biol. 2022 Jan;23(1):21-39. (PMID: 34824452) ACS Omega. 2022 Jan 11;7(3):2960-2969. (PMID: 35071937) Mol Biotechnol. 2023 Jan 24;:. (PMID: 36690820) Signal Transduct Target Ther. 2021 Dec 6;6(1):414. (PMID: 34873151) BMJ. 2021 Mar 10;372:n436. (PMID: 33692022) Nat Rev Microbiol. 2021 Mar;19(3):155-170. (PMID: 33116300) N Engl J Med. 2022 Feb 10;386(6):509-520. (PMID: 34914868) ACS Bio Med Chem Au. 2022 Oct 24;2(6):565-585. (PMID: 37582236) N Engl J Med. 2023 Feb 2;388(5):406-417. (PMID: 36577095) Adv Sci (Weinh). 2020 Oct;7(19):e2001435. (PMID: 35403380) Eur J Med Chem. 2021 Mar 5;213:113201. (PMID: 33524687) Curr Res Pharmacol Drug Discov. 2021;2:100055. (PMID: 34870153) Front Med (Lausanne). 2023 Mar 14;10:1143485. (PMID: 37007788) N Engl J Med. 2022 Apr 14;386(15):1397-1408. (PMID: 35172054) ACS Omega. 2023 Jan 30;8(6):5234-5246. (PMID: 36798145) |
| فهرسة مساهمة: | Keywords: Azvudine (FNC); RNA-dependent RNA polymerase; nucleic acid-negative conversion time; severe acute respiratory syndrome coronavirus 2; viral load |
| تواريخ الأحداث: | Date Created: 20230911 Latest Revision: 20230913 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC10484631 |
| DOI: | 10.3389/fphar.2023.1228548 |
| PMID: | 37693894 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1663-9812 |
|---|---|
| DOI: | 10.3389/fphar.2023.1228548 |